关键信息
-
基因名
BEGAIN
- 应用
-
别名
Begain; BEGIN; BEGIN_HUMAN; Brain enriched guanylate kinase associated Protein
-
种属
Human
-
表达系统
E. coli
-
标签
GST-tag at N-terminal
-
纯度
Greater than 90% as determined by SDS-PAGE.
-
蛋白编号
Q9BUH8
-
表达区间
1-593aa
-
氨基酸序列
MEKLSALQEQ KGELRKRLSY TTHKLEKLET EFDSTRHYLE IELRRAQEEL EKVTEKLRRI QSNYMALQRI NQELEDKLYR MGQHYEEEKR ALSHEIVALN SHLLEAKVTI DKLSEDNELY RKDCNLAAQL LQCSQTYGRV HKVSELPSDF QERVSLHMEK HGCSLPSPLC HPAYADSVPT CVIAKVLEKP DPASLSSRLS DASARDLAFC DGVEKPGPRP PYKGDIYCSD TALYCPEERR RDRRPSVDAP VTDVGFLRAQ NSTDSAAEEE EEAEAAAFPA GFQHEAFPSY AGSLPTSSSY SSFSATSEEK EHAQASTLTA SQQAIYLNSR DELFDRKPPA TTYEGSPRFA KATAAVAAPL EAEVAPGFGR TMSPYPAETF RFPASPGPQQ ALMPPNLWSL RAKPGTARLP GEDMRGQWRP LSVEDIGAYS YPVSAAGRAS PCSFSERYYG GAGGSPGKKA DGRASPLYAS YKADSFSEGD DLSQGHLAEP CFLRAGGDLS LSPGRSADPL PGYAPSEGGD GDRLGVQLCG TASSPEPEQG SRDSLEPSSM EASPEMHPAA RLSPQQAFPR TGGSGLSRKD SLTKAQLYGT LLN
-
分子量
91.2 kDa
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
质检流程
相关产品
背景信息
BEGAIN is a recombinant protein that has garnered significant attention due to its unique structural and functional properties, which make it a valuable subject of research in various fields, including biochemistry, molecular biology, and therapeutic development. The protein is derived from the BEGAIN gene, whose expression is modulated in response to specific physiological conditions. Recent studies have suggested that BEGAIN plays a pivotal role in cellular signaling pathways, influencing processes such as cell proliferation, differentiation, and stress responses. Researchers are particularly interested in the potential applications of BEGAIN in regenerative medicine and cancer therapy, as its recombinant form can be engineered to enhance its stability and affinity for therapeutic targets. Furthermore, the ability to produce BEGAIN in a recombinant system allows for large-scale production and purification, facilitating detailed studies on its biochemical properties and interactions with other proteins. Understanding the mechanisms through which BEGAIN operates may provide insights into novel treatment strategies for diseases linked to its dysregulation. As such, ongoing research aims to elucidate the structure-function relationship of BEGAIN, explore its interaction networks, and assess its therapeutic potential, thereby paving the way for innovative solutions to pressing medical challenges.
